Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTXHJ9)

Drug Name

Sirolimus Drug Info

Synonyms

Rapammune; Sirolimus; Rapamycin; I2190A; 53123-88-9; (-)-Rapamycin; Wy 090217; SIIA 9268A; Rapamune; I-2190A; AY-22989; RAPA; NSC 226080; I 2190A; AY 22989; Rapamycin (Sirolimus); WY-090217; Antibiotic AY 22989; UNII-W36ZG6FT64; SILA 9268A; CHEBI:9168; CCRIS 9024; W36ZG6FT64; HSDB 7284; C51H79NO13; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Supralimus; Sirolimus

Indication

Disease Entry	ICD 11	Status	REF
Lymphangioleiomyomatosis	CB07	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[2]

Therapeutic Class

Antiviral Agents

Cross-matching ID

PubChem CID: 5284616
ChEBI ID: CHEBI:9168
CAS Number: CAS 53123-88-9
TTD Drug ID: DMTXHJ9
ACDINA Drug ID: D00627

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting HUMAN mammalian target of rapamycin (mTOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rapamycin	DM8GRJK	Lymphangioleiomyomatosis	CB07	Investigative	[4]
Everolimus	DM17TYR	Advanced/metastatic breast cancer	2C60	Investigative	[4]
Sapanisertib	DMYZFNH	Breast cancer	2C60-2C65	Investigative	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HUMAN mammalian target of rapamycin (mTOR)	TT7HQAF	MTOR_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 201578.
2	ClinicalTrials.gov (NCT04341675) Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia. U.S. National Institutes of Health.
3	Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020 Mar 16;6:14.
4	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
5	Prevent COVID-19 Severity by Repurposing mTOR Inhibitors. 2 April 2020